Loading…
Opioid Abuse Prevention and Treatment Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
37pct
1d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Opioid Abuse Prevention and Treatment Act of 2017 This bill requires the Department of Health and Human Services (HHS) to award grants to states to develop a peer review process to identify and investigate questionable or inappropriate prescribing and dispensing patterns of drugs classified as schedule II or III under the Controlled Substances Act, which are drugs with an accepted medical use that have the potential to be abused and addictive. This bill amends the Public Health Service Act to require HHS to establish grant programs to: (1) facilitate training to increase the capacity of health care providers to screen and treat patients to prevent drug abuse, and (2) develop continuing education criteria that allow health profession boards or state agencies to certify appropriate education for safe prescribing of schedule II or III drugs. The Health Resources and Services Administration must award grants to evaluate the prospect of state health professions boards expanding the authority of providers to prescribe drugs to treat drug abuse. The Drug Enforcement Administration must request that practitioners registered to dispense controlled substances screen patients for potential drug abuse before prescribing a schedule II or III drug. The Food and Drug Administration must consider whether naloxone (a prescription drug used to rapidly reverse an overdose of heroin or other opioids, which are drugs with effects similar to opium) should be available without a prescription. HHS must convene or coordinate with an interagency working group to encourage states and local governments to increase opportunities for disposal of opiates (drugs derived from opium) and to reduce opportunities for abuse of opiates. The Government Accountability Office must review federal opioid abuse activities and make recommendations to reduce opioid abuse and overdoses.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2018 · fourth_quarter · Medical/Disease Research/Clinical Labs
Issues related to the promotion of continuing medical education (CME) and the implementation of the Physician Payment Sunshine Act. Implementation issues related to the Medicare Access and CHIP Reauthorization Act of 2015, P.L.114-10. Issues related to the role of continuing medical education (CME) and Food and Drug Administration (FDA) opioid REMS; SUPPORT for Patients and Communities Act (H.R.6/P.L.115-271); Opioid Prevention and Treatment Act of 2017 (H.R.993); Improve Addiction Education Act (H.R.4075); ADAPT Act (H.R.5581); REACH OUT Act (H.R.5796).
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Alcohol and Drug Abuse
S. 1327, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R. 2851, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R.993, Opioid Abuse Prevention and Treatment Act of 2017 H.R. 1732, Synthetic Drug Control Act of 2017 H.R.5298, Modernizing Drug Enforcement Act of 2018
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Medical/Disease Research/Clinical Labs
Issues related to the promotion of continuing medical education (CME) and the implementation of the Physician Payment Sunshine Act. Implementation issues related to the Medicare Access and CHIP Reauthorization Act of 2015, P.L.114-10. Issues related to the role of continuing medical education (CME) and Food and Drug Administration (FDA) opioid REMS; SUPPORT for Patients and Communities Act (H.R.6); Opioid Prevention and Treatment Act of 2017 (H.R.993); Improve Addiction Education Act (H.R.4075); ADAPT Act (H.R.5581); REACH OUT Act (H.R.5796).
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Alcohol and Drug Abuse
S. 1327, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R. 2851, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R.993, Opioid Abuse Prevention and Treatment Act of 2017
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Medical/Disease Research/Clinical Labs
Issues related to the promotion of continuing medical education (CME) and the implementation of the Physician Payment Sunshine Act. Implementation issues related to the Medicare Access and CHIP Reauthorization Act of 2015, P.L.114-10. Issues related to the role of continuing medical education (CME) and Food and Drug Administration (FDA) opioid REMS; SUPPORT for Patients and Communities Act (H.R.6); Opioid Prevention and Treatment Act of 2017 (H.R.993); Improve Addiction Education Act (H.R.4075); ADAPT Act (H.R.5581); REACH OUT Act (H.R.5796).
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Alcohol and Drug Abuse
S. 1327, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R. 2851, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R.993, Opioid Abuse Prevention and Treatment Act of 2017
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Alcohol and Drug Abuse
S. 1327, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R. 2851, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R.993, Opioid Abuse Prevention and Treatment Act of 2017 S.Res.301 - A resolution designating the week beginning on October 22, 2017, as "National Chemistry Week"
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Medicare/Medicaid
Administrative and legislative monitoring and outreach on issues related to healthcare. H.R. 993, Opioid Abuse Prevention and Treatment Act of 2017.
Client expense: Not reported · Firm income: $120,000
Government targets: White House Office
2017 · third_quarter · Health Issues
Administrative and legislative monitoring and outreach on issues related to healthcare. H.R. 993, Opioid Abuse Prevention and Treatment Act of 2017.
Client expense: Not reported · Firm income: $120,000
Government targets: White House Office
2017 · third_quarter · Alcohol and Drug Abuse
S. 1327, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R. 2851, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R.993, Opioid Abuse Prevention and Treatment Act of 2017
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Alcohol and Drug Abuse
H.R.993 - Opioid Abuse Prevention and Treatment Act of 2017
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| NY |